Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.

Acticor Biotech SAS

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.

Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. 
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. 

However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.

This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Mediolanum Farmaceutici S.p.A.

Mirae Capital

Newton Biocapital

CMS Medical Venture Investment

Karista

Mirae Asset

GO CAPITAL

A&B (HK)

Anaxago

Acticor Biotech

[#GlenzoPaper]

🌟 Exciting News! ACTIMIS Clinical Study Results have been officially published in The Lancet Neurology Journal 🧠🌐 

📰 Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial 

🔎 This article highlights key outcomes from the ACTIMIS study : 

✅ Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in acute ischemic stroke patients

📉 Reduction in the rate and severity of intracranial hemorrhages and of mortality in glenzocimab-treated patients

🔗Access the full paper on The Lancet website : https://lnkd.in/etYUfpMq

#ACTIMIS #MedicalResearch #StrokeTreatment #HealthcareInnovation

[#GlenzoPaper]

🎙️ Gilles Avenard, CEO d'Acticor Biotech, revient sur la parution des résultats d'ACTIMIS dans The Lancet lors d'un entretien avec Nathalie Brafman dans Le Monde 🌍 

🔗 Lien vers l'article : https://lnkd.in/e-Pu4jnu

#interview #ACTIMIS #LeMonde

[#GlenzoPaper]

"AVC - l'anticorps d'une biotech française qui pourrait réduire de moitié le risque de décès" 🚑 

✍ Publié dans Le Figaro, cet article revient sur la publication des résultats de l'étude ACTIMIS dans The Lancet Neurogoly avec le témoignage du Pr. Charlotte Cordonnier - chef du service de neurologie vasculaire au CHU de Lille et celui du Pr. Mikael Mazighi - chef du service de neurologie à l'hôpital Lariboisère 🗣 📰

Lien de l'article : https://lnkd.in/ewMunHan 🌐 

#ACTIMIS #interview #glenzocimab

[#GlenzoPaper]

Aujourd'hui, le Pr. Mikael Mazighi, chef de la neurologie à l'hôpital Lariboisière et coordinateur principal de l'étude ACTIMIS, était invité dans le Journal de 8h animé par Florence Paracuellos sur France Inter 🎙️

Il a partagé plus en détail les résultats de l'étude récemment publiés dans The Lancet ! 📊

Si vous avez manqué l'interview, vous pouvez trouver le podcast du journal ici (01:29 - 03:10) :  https://lnkd.in/eWVhdYwJ
Et pour plus d'infos, jetez un œil à l'article : https://lnkd.in/e9m5zqMs 📰

#ACTIMIS #interview #glenzocimab 

	Jun '14	Jun '15	Jun '16	Jun '17	Jun '18	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Jun '24
revenue
cost of revenue							51K -		49K -		36K -		50K -		7K -		721K -
gross profit							-51K -		-49K -		-36K -		-50K -		-7K -		-721K -
selling and marketing expenses						65 -	1.30M 2,002,012.31%		2.72M -	224 99.99%	2.30M 1,028,045.54%	343 99.99%	2.26M 657,685.71%
general and administrative expenses						627 -	627 0%					795 -	795 0%
selling general and administrative expenses						692 -	1.30M 188,050.29%	1.38K 99.89%	2.72M 197,863.64%		2.30M -	1.14K 99.95%	2.26M 198,230.40%		2.86M -	1.39K 99.95%	2.02M 145,256.37%	2.69M 33.43%
research and development expenses							5.66M -		5.11M -	3.12K 99.94%	6.24M 199,867.94%		6.89M -	3.54K 99.95%	12.11M 342,167.46%	3.71K 99.97%	2.14M 57,505.18%	4.25M 98.92%
other expenses															-25K -		-40K -
cost and expenses							7.02M -	3.14K 99.96%	7.88M 251,031.65%	3.65K 99.95%	8.58M 234,564.84%		9.20M -		15.00M -		4.92M -	6.94M 41.23%
operating expenses						2.87K -	6.96M 242,625.21%	3.14K 99.95%	7.83M 249,469.65%	3.65K 99.95%	8.54M 233,579.89%	4.13K 99.95%	9.15M 221,686.02%	4.41K 99.95%	14.99M 339,816.11%	4.68K 99.97%	4.20M 89,565.49%	6.94M 65.51%
interest expense													378K -		1.74M -		403K -	240K 40.45%
ebitda						-2.85K -	-6.96M 244,715.47%		-7.83M -	-3.61K 99.95%	-8.54M 236,623.95%	-3.92K 99.95%	-9.15M 233,548.20%		-14.99M -		-4.20M -	-7.07M 68.41%
operating income							-7.02M -		-7.88M -	-3.63K 99.95%	-8.58M 235,855.98%		-9.20M -		-15.00M -	-4.37K 99.97%	-4.92M 112,342.82%	-6.94M 41.23%
depreciation and amortization							51K -	12 99.98%	49K 408,233.33%	27 99.94%	36K 133,233.33%		50K -		7K -		721K -	-122K 116.92%
total other income expenses net							330K -		20K -	-20 100.10%	244K 1,220,100%		-481K -	-630 99.87%	-1M 158,630.16%		181K -	-362K 300%
income before tax						-2.95K -	-6.69M 226,313.82%	-3.35K 99.95%	-7.86M 234,397.17%	-3.65K 99.95%	-8.33M 227,889.06%	-4.28K 99.95%	-9.68M 225,927.08%		-16.00M -		-4.74M -	-7.30M 54.28%
income tax expense							-780K -		-1.16M -		-1.02M -		-1.11M -		-5.92M -		3.82M -
net income						-2.95K -	-5.91M 199,900%	-3.35K 99.94%	-6.70M 199,900%	-3.65K 99.95%	-7.31M 199,900%	-4.28K 99.94%	-8.57M 199,900%	-5.04K 99.94%	-10.08M 199,900%	-4.28K 99.96%	-8.56M 199,900%	-7.30M 14.65%
weighted average shs out	10.48M -	10.48M 0%	10.48M 0%	10.48M 0%	10.48M 0%	7.85K 99.93%	10.55M 134,189.77%	7.69K 99.93%	10.55M 136,982.75%	10.54K 99.90%	10.55M 99,907.36%	10.54K 99.90%	10.55M 99,907.36%	11.59K 99.89%	11.63M 100,284.40%	12.51K 99.89%	12.63M 100,876.89%	15.76M 24.77%
weighted average shs out dil	10.48M -	10.48M 0%	10.48M 0%	10.48M 0%	10.48M 0%		10.55M -		10.55M -	10.54K 99.90%	10.55M 99,907.36%	10.54K 99.90%	10.55M 99,907.36%	11.63K 99.89%	11.63M 99,904.64%	12.51K 99.89%	12.63M 100,876.89%	15.76M 24.77%
eps	0 -	0	0	0	0	-0.38 Infinity%	-0.56 47.37%	-0.44 21.43%	-0.64 45.45%	-0.35 45.31%	-0.69 97.14%	-0.41 40.58%	-0.81 97.56%	-0.44 45.68%	-0.87 97.73%	-0.34 60.92%	-0.68 100%	-0.46 32.35%
epsdiluted	0 -	0	0	0	0	-0.38 Infinity%	-0.56 47.37%	-0.43 23.21%	-0.64 48.84%	-0.35 45.31%	-0.69 97.14%	-0.41 40.58%	-0.81 97.56%	-0.43 46.91%	-0.87 102.33%	-0.34 60.92%	-0.68 100%	-0.46 32.35%

COM:ACTICOR-BIOTECH

Acticor Biotech

Last Close

0.30

25/11 08:00

Market Cap

8.67M

Beta: -

Volume Today

50

Avg: -

Preview